Santa Ana, CA, United States (4E) – Medical business marketing strategist BioWyze LLC will promote the addiction treatment product of BioCorRx (OTCQB: BICX) and enhance the latter’s market penetration, according to the two companies’ consulting agreement forged last week.
Under the deal that will take effect Monday, BioWyze will develop and use a customized business model that will position BioCorRx to achieve an increased marketable value. The model is designed to provide synergies between current licensees of Start Fresh Program, founders, corporate executives and other business stakeholders to meet corporate objectives and stated goals.
BioWyze leaders and managers will execute the plan, including managing partners Jeff Bagshaw, Rich Maloy, Vicky Robinson, Tobin Geatz, Grace Granato, and Jeff Reiniche.
BioCorRx licenses Start Fresh Program to drug and alcohol addiction rehabilitation clinics across the country. The program involves the use of an implant that delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program is a one-on-one coaching tailored for the treatment of alcoholism and other substance abuse addictions. Clinic reports show that the treatment program has an extremely high success rate with individuals that complete the program.
BioCorRx, Inc. CEO Kent Emry said the company will benefit greatly from the expertise of BioWyze, whose clients also include Actavis plc (NYSE:ACT), LipoScience Inc. (Nasdaq:LPDX) and Exact Sciences (NASDAQ:EXAS).
“BioCorRx is entering an exciting growth phase of its business, and we are honored to have been selected by the leadership team to support their strategic corporate goals,” Bagshaw, said of the partnership. “Supporting our licensees’ expansion within their served market is a priority and will be an important function moving forward, as will be the identification of other expansion verticals along with the development of technology solutions.”
Bagshaw has over 25 years of experience in clinical development, sales, marketing and product commercialization in health care. His experience includes leadership roles at contract research company Inclinix, Inc., and Hoffman La Roche, Bristol Myers Squibb and Exact Sciences.
BioWyze is also a consultant of Actavis, which develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories.
Actavis reported last month anet revenue of $2.67 billion for the second quarter ending on June 30. The figure is 34 percent higher than the net profit in the same period last year. It operates in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.